L-carnitine is an amino acid derivative of lysine and Methionine which may be used in CRF patients as an adjuvant therapy either to improve anaemia or reduce erythropoietin request or to improve uraemic dyslipidaemia. The aim of the study is to delineate the effect of L-carnitine on anaemia, erythropoietin request and lipid profile parameters. 40 patients on regular haemodialysis from police authority hospital were divided into 4 groups according to supplementation of L-carnitine and erythropoietin, group A and C received L-carnitine 10 mg/kg/oral form while group B and D received inert placebo. Also, group A and B were already on erythropoietin dose maintaining their Hb at 9-12 g/dl while group C and D had never received erythropoietin. The four groups were already supplemented and maintained on other anti anaemia measures. Any patient who was under any drug or factor which may affect erythropoietin or haemoglobin before or throughout the study was excluded. Erythropoietin request, haemoglobin, cholesterol, triglycerides and lipoprotein (a) were assayed before and after the study. We found that L-carnitine was useful in decreasing r-HuEPO request, improving anaemia and also improving uraemic dyslipidaemia. This was clear in group C in which Hb post test increased significantly p < 0.01. Also, r HuEPO in group A decreased significant p < 0.01. Regarding cholesterol, it decreased in both group A and C significantly “p < 0.01, p < 0.05 respectively”. Also, triglycerides decreased in group A and C significantly “p < 0.01, p < 0.05 respectively”. In addition to the significant decrease in Lipoprotein (a) in group A and C “p < 0.01, p < 0.05 respectively”. So we can conclude that L-carnitine is a useful agent in decreasing r-HuEPO request, improving anaemia and also improving uraemic dyslipidaemia.